Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPTH(1-84) PK/PD in Japanese and Caucasian Healthy Subjects
NCT03150108Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2017
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of parathyroid hormone 1-84 in hypoparathyroidism (2 arms), sponsored by Takeda. Primary endpoints: Maximum Plasma Concentration at Day 7, Time to Maximum Plasma Concentration at Day 7 and 1 more. Started May 2017; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT03150108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150108.